PharmaEssentia's BESREMi faces Aug. 30 FDA decision in essential thrombocythemia
The sBLA seeks the first U.S. label expansion of an already-approved interferon into a second blood-cancer indication, with Taiwan's approval in hand and no BESREMi-specific data disclosed yet.
Executive Summary
- PharmaEssentia is awaiting an FDA decision on whether to expand BESREMi's U.S. label from polycythemia vera into essential thrombocythemia, resting on a Phase 3 trial that finished enrollment and reached its primary completion date well before the review clock started.
- Because BESREMi is already approved and has already cleared regulators in Taiwan for this same indication, the U.S. review is a bridging question about replicating an established profile, not a first-time efficacy bet.
- The interferon-alpha receptor mechanism has few direct rivals in essential thrombocythemia, and the therapies furthest along in that indication work through unrelated mechanisms, leaving BESREMi with limited head-to-head pressure but also limited external validation of its own pathway in this setting.
- An approval would give PharmaEssentia a second U.S. indication for its only commercial product and formalize a commercial buildout the company has already begun ahead of the decision.
The submission
The FDA has set a target action date of August 30, 2026 for PharmaEssentia's supplemental BLA seeking to add essential thrombocythemia to BESREMi's U.S. label, which currently covers polycythemia vera. The application rests on NCT04285086, the SURPASS ET trial comparing ropeginterferon alfa-2b against anagrelide in patients with essential thrombocythemia who are resistant or intolerant to hydroxyurea, run across sites in Taiwan, China, Japan, South Korea, Canada, the United States, Singapore and Hong Kong. PharmaEssentia hired Eric Vogel, formerly of Incyte's oncology and hematology sales organization, as U.S. Head of Commercialization in May 2026, explicitly to prepare for a potential U.S. launch in essential thrombocythemia. PharmaEssentia+1PharmaEssentia Appoints Eric Vogel as U.S. Head of Commercialization Ahead of Potential Launch of BESREMi® in Essential ThrombocythemiaMay 27, 2026Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or IntoleranceNCT04285086
Trial status
The trial enrolled 174 patients, up from an original target of 160, and moved to Active, not recruiting status in November 2023. Its primary completion date has shifted six times since 2020, moving from February 2022 to November 12, 2024, the most recent revision recorded in August 2025. No primary endpoint result, effect size, or safety profile from this trial has posted on ClinicalTrials.gov. The trial's overall completion date is not due until August 2029, reflecting continued follow-up beyond the primary analysis that underlies the pending submission. NCT04285086Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or IntoleranceNCT04285086
Regulatory precedent
Taiwan's Ministry of Health and Welfare approved BESREMi for adult essential thrombocythemia patients on June 10, 2026, ahead of the U.S. decision. PharmaEssentia has also filed for the same indication in Japan, China and South Korea. Because BESREMi is already approved in the United States for polycythemia vera, the U.S. review of the essential thrombocythemia application is a question of whether the SURPASS ET data reproduce a comparable clinical benefit in a related myeloproliferative disease, not a first-time review of a novel biologic. PharmaEssentiaPharmaEssentia Appoints Eric Vogel as U.S. Head of Commercialization Ahead of Potential Launch of BESREMi® in Essential ThrombocythemiaMay 27, 2026
The competitive field
Three active industry trials study the IFNAR1 target in essential thrombocythemia, and one prior trial in this target-indication pairing has completed without termination. The most advanced rival programs in essential thrombocythemia work through different mechanisms: Incyte's INCA033989 and Merck's bomedemstat, both in Phase 3, target pathways distinct from the interferon-alpha receptor BESREMi engages. That leaves ropeginterferon alfa-2b without a direct mechanistic competitor at Phase 3 in this indication, though it also means no rival trial result yet exists to benchmark the interferon-receptor approach specifically in hydroxyurea-resistant essential thrombocythemia.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.